RHHBY•benzinga•
Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%
Summary
Roche's APHINITY study shows promising results for HER2-positive breast cancer treatment with Perjeta regime
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 13, 2025 by benzinga